Friends! In this video, I'm going to do an Intel stock analysis & discuss the risks and upside potential of INTC stock
1 extracted signal · 1 resolved · 0 still active
The Patient InvestorIndependent analyst profile- Source published
- 23 Jan 2026, 19:33 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC

AI-generated source summary
Intel reported earnings per share of 15 cents (adjusted) against 8 cents expected and revenue of $13.7 billion versus $13.4 billion expected, indicating a beat on both metrics. However, the company's Q1 guidance for 2026 was significantly below expectations, causing the stock to drop 11% in after-hours trading to $48.26. The computer chip segment revenue declined quarter-over-quarter, but the AI chip segment showed reacceleration and operating margin expansion (from 23% to 26%). The Intel Foundry business remains unprofitable with negative 55.7% operating margins but is seen as a national security investment to bring chip manufacturing to the US. Intel recently sold $5.0 billion of common stock to NVIDIA to fund capital expenditures for scaling the foundry, which has led to diluted shares outstanding. Despite current valuation metrics appearing high (126x depressed earnings), the company is expected to become profitable, with EPS projected to reach $1.97 by 2028. Based on a 25x earnings multiple on 2028 EPS, a long-term target of $71 is calculated for 2030. The analyst, however, believes Intel is currently overvalued and would only consider buying at $35.50 per share to achieve a potential double.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
